

Minoli A Perera

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2943764/minoli-a-perera-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38
papers

1,184
citations

17
h-index

34
g-index

46
ext. papers

1,453
ext. citations

6.7
avg, IF

4.22
L-index

| # | Paper | IF | Citations |
|----|---|-----|-----------|
| 38 | Genetic association of primary nonresponse to anti-TNF α therapy in patients with inflammatory bowel disease. <i>Pharmacogenetics and Genomics</i> , 2022 , 32, 1-9 | 1.9 | 0 |
| 37 | Incorporation of DNA methylation into eQTL mapping in African Americans. <i>Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing</i> , 2021 , 26, 244-255 | 1.3 | |
| 36 | Differences in the Platelet mRNA Landscape Portend Racial Disparities in Platelet Function and Suggest Novel Therapeutic Targets. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 702-713 | 6.1 | 1 |
| 35 | Impact of CYP2C9-Interacting Drugs on Warfarin Pharmacogenomics. <i>Clinical and Translational Science</i> , 2020 , 13, 941-949 | 4.9 | 4 |
| 34 | Why African Americans say "No": A Study of Pharmacogenomic Research Participation. <i>Ethnicity and Disease</i> , 2020 , 30, 159-166 | 1.8 | 3 |
| 33 | Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 1420-1433 | 6.1 | 20 |
| 32 | Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation. <i>Pharmacogenomics Journal</i> , 2020 , 20, 126-135 | 3.5 | 8 |
| 31 | Discovery of novel hepatocyte eQTLs in African Americans. <i>PLoS Genetics</i> , 2020 , 16, e1008662 | 6 | 9 |
| 30 | Discovery of novel hepatocyte eQTLs in African Americans 2020 , 16, e1008662 | | |
| 29 | Discovery of novel hepatocyte eQTLs in African Americans 2020 , 16, e1008662 | | |
| 28 | Discovery of novel hepatocyte eQTLs in African Americans 2020 , 16, e1008662 | | |
| 27 | Discovery of novel hepatocyte eQTLs in African Americans 2020 , 16, e1008662 | | |
| 26 | The ACCOuNT Consortium: A Model for the Discovery, Translation, and Implementation of Precision Medicine in African Americans. <i>Clinical and Translational Science</i> , 2019 , 12, 209-217 | 4.9 | 17 |
| 25 | On Using Local Ancestry to Characterize the Genetic Architecture of Human Traits: Genetic Regulation of Gene Expression in Multiethnic or Admixed Populations. <i>American Journal of Human Genetics</i> , 2019 , 104, 1097-1115 | 11 | 23 |
| 24 | The Advantages and Challenges of Diversity in Pharmacogenomics: Can Minority Populations Bring Us Closer to Implementation?. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 338-349 | 6.1 | 17 |
| 23 | Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 1077-1089 | 6.2 | 9 |
| 22 | Leaving some behind: the growing gap in precision medicine for minority populations. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019 , 4, 3-5 | 1.6 | 1 |

| | | | |
|----|---|------|-----|
| 21 | Hepatocyte gene expression and DNA methylation as ancestry-dependent mechanisms in African Americans. <i>Npj Genomic Medicine</i> , 2019 , 4, 29 | 6.2 | 3 |
| 20 | A Review of African Americans' Beliefs and Attitudes About Genomic Studies: Opportunities for Message Design. <i>Frontiers in Genetics</i> , 2019 , 10, 548 | 4.5 | 20 |
| 19 | Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White?. <i>Annual Review of Pharmacology and Toxicology</i> , 2019 , 59, 577-603 | 17.9 | 12 |
| 18 | Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 778-786 | 6.1 | 63 |
| 17 | Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes. <i>Pharmacogenomics Journal</i> , 2018 , 18, 106-112 | 3.5 | 3 |
| 16 | Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 1670-1677 | 27.4 | 22 |
| 15 | Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 735-743 | 15.4 | 2 |
| 14 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 397-404 | 6.1 | 320 |
| 13 | Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms. <i>Pharmacogenomics Journal</i> , 2017 , 17, 494-500 | 3.5 | 14 |
| 12 | Novel genetic predictors of venous thromboembolism risk in African Americans. <i>Blood</i> , 2016 , 127, 1923-9 | 2.2 | 28 |
| 11 | Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms. <i>Pharmacogenomics</i> , 2015 , 16, 217-25 | 2.6 | 11 |
| 10 | Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans. <i>Translational Research</i> , 2015 , 165, 651-7 | 11 | 6 |
| 9 | Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. <i>Pharmacogenomics Journal</i> , 2014 , 14, 223-8 | 3.5 | 50 |
| 8 | Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. <i>Blood</i> , 2014 , 124, 2298-305 | 2.2 | 49 |
| 7 | Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. <i>Lancet, The</i> , 2013 , 382, 790-6 | 40 | 191 |
| 6 | Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. <i>Pharmacogenomics</i> , 2012 , 13, 1925-35 | 2.6 | 52 |
| 5 | The future of warfarin pharmacogenetics in under-represented minority groups. <i>Future Cardiology</i> , 2012 , 8, 563-76 | 1.3 | 48 |
| 4 | The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 408-15 | 6.1 | 94 |

| | | | |
|---|---|-----|----|
| 3 | The missing linkage: what pharmacogenetic associations are left to find in CYP3A?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010 , 6, 17-28 | 5.5 | 36 |
| 2 | Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?. <i>Pharmacotherapy</i> , 2008 , 28, 755-68 | 5.8 | 46 |
| 1 | Uncovering the role of admixture in disease and drug response: Association of hepatocyte gene expression and DNA methylation with African Ancestry in African Americans | | 2 |